A Randomised Phase II Feasibility Study of Docetaxel plus Prednisolone vs Docetaxel plus Prednisolone plus Zoledronic acid vs docetaxel plus Prednisolone plus Strontium-89 vs Docetaxel plus prednisolone plus Zoledronic acid plus Strontium-8

James, Nicholas (Principal Investigator)

Cancer and Genomic Sciences

1 Article

1 results

2017
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
Andronis, L., Goranitis, I., Pirrie, S., Pope, A., Barton, D., Collins, S., Daunton, A., McLaren, D., O'Sullivan, J. M., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J. E., Chakraborti, P., Hussain, S. A., Russell, J. M., & 2 othersBillingham, L. J. & James, N. D., Apr 2017, In: BJU international. 119, 4, p. 522-529 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
11 Citations (Scopus)

281 Downloads (Pure)